Ophthalmic Research
Original Paper
Dexamethasone Implants in Diabetic Macular Edema Patients with High Visual AcuitySacconi R.a, b · Battaglia Parodi M.b · Casati S.a · Lattanzio R.b · Marchini G.a · Bandello F.baEye Clinic, Department of Neurological, Biomedical, and Movement Sciences, University of Verona, Verona, and bDepartment of Ophthalmology, IRCCS Ospedale San Raffaele, University Vita-Salute, Milano, Italy
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Received: April 24, 2017
Accepted: May 04, 2017
Published online: July 14, 2017
Issue release date: September 2017
Number of Print Pages: 6
Number of Figures: 2
Number of Tables: 1
ISSN: 0030-3747 (Print)
eISSN: 1423-0259 (Online)
For additional information: https://www.karger.com/ORE
Abstract
Purpose: To evaluate the effects of intravitreal dexamethasone (DEX) implants in patients affected by diabetic macular edema (DME) with high best-corrected visual acuity (BCVA) and contraindications to therapy with anti-vascular endothelial growth factor over a 12-month follow-up. Methods: In this interventional nonrandomized clinical study, 14 consecutive patients (14 eyes) affected by DME with a BCVA of 0.3 LogMAR or better were prospectively enrolled. All patients were treated with a sustained-release 700-μg DEX implant at baseline, revaluated every 6 weeks, and retreated on a pro re nata basis. Primary outcomes included changes in BCVA and central macular thickness (CMT). Secondary outcomes included number of implants, average period between injections, and incidence of side effects. Results: At the 12-month examination, a significant improvement in mean BCVA was noted compared to baseline (from 0.25 ± 0.05 to 0.10 ± 0.07 LogMAR; p < 0.001); CMT decreased from 484 ± 127 to 311 ± 51 μm (p < 0.001). No differences in BCVA and CMT improvements were found between treatment- naïve patients and previously treated patients (p = 0.768 and 0.119, respectively). The mean number of implants was 1.71 ± 0.61 (range, 1-3). The mean period between the first and the second implant was 6.1 ± 1.6 months. Conclusions: The DEX implant on a pro re nata basis can be considered a beneficial approach for DME patients with high BCVA over a 12-month follow-up; functional and anatomical outcome of the patients significantly improved with few injections and a good safety profile.
© 2017 S. Karger AG, Basel
References
-
Fong DS, Aiello LP, Ferris FL 3rd, Klein R: Diabetic retinopathy. Diabetes Care 2004;27:2540-2553.
-
Gillies MC, Lim LL, Campain A, et al: A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX Study. Ophthalmology 2014;121:2473-2481.
-
Das A, McGuire PG, Rangasamy S: Diabetic macular edema: pathophysiology and novel therapeutic targets. Ophthalmology 2015;122:1375-1394.
-
Semeraro F, Cancarini A, dell'Omo R, et al: Diabetic retinopathy: vascular and inflammatory disease. J Diabetes Res 2015;2015:582060.
-
American Diabetes Association: Standards of medical care in diabetes - 2012. Diabetes Care 2012;35(suppl 1):S11-S63.
-
Nguyen QD, Brown DM, Marcus DM, et al; RISE and RIDE Research Group: Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 2012;119:789-801.
-
Brown DM, Nguyen QD, Marcus DM, et al; RIDE and RISE Research Group: Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 2013;120:2013-2022.
-
Edelman JL, Lutz D, Castro MR: Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown. Exp Eye Res 2005;80:249-258.
-
Boyer DS, Yoon YH, Belfort R Jr, et al; Ozurdex MEAD Study Group: Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 2014;121:1904-1914.
-
Fraser-Bell S, Lim LL, Campain A, et al: Bevacizumab or dexamethasone implants for DME: 2-year results (the BEVORDEX Study). Ophthalmology 2016;123:1399-1401.
-
Dutra Medeiros M, Postorino M, Navarro R, et al: Dexamethasone intravitreal implant for treatment of patients with persistent diabetic macular edema. Ophthalmologica 2014;231:141-146.
-
Zhioua I, Semoun O, Lalloum F, Souied EH: Intravitreal dexamethasone implant in patients with ranibizumab persistent diabetic macular edema. Retina 2015;35:1429-1435.
-
Iacono P, Parodi MB, Scaramuzzi M, Bandello F: Morphological and functional changes in recalcitrant diabetic macular oedema after intravitreal dexamethasone implant. Br J Ophthalmol 2017;101:791-795.
-
Haller JA, Kuppermann BD, Blumenkranz MS, et al; Dexamethasone DDS Phase II Study Group: Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol 2010;128:289-296.
-
Gillies MC, Sutter FK, Simpson JM, et al: Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 2006;113:1533-1538.
-
Scaramuzzi M, Querques G, Spina CL, et al: Repeated intravitreal dexamethasone implant (Ozurdex) for diabetic macular edema. Retina 2015;35:1216-1222.
-
Mastropasqua R, Toto L, Borrelli E, et al: Morphology and function over a one-year follow up period after intravitreal dexamethasone implant (Ozurdex) in patients with diabetic macular edema. PLoS One 2015;10: e0145663.
Article / Publication Details
Received: April 24, 2017
Accepted: May 04, 2017
Published online: July 14, 2017
Issue release date: September 2017
Number of Print Pages: 6
Number of Figures: 2
Number of Tables: 1
ISSN: 0030-3747 (Print)
eISSN: 1423-0259 (Online)
For additional information: https://www.karger.com/ORE
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
